Market Overview:

According to a new report by IMIR Market Research on Global Epigenetics Market in terms of revenue was estimated to be worth USD 1.9 billion in 2023 and is poised to reach USD 8.96 billion by 2032, growing at a CAGR of 18.8% from 2024 to 2032.

The rapid rate that the research is progressing is caused by the increase in research funds as well as investments in making epigenetics development in science as well as a rise in the applications of epigenetics in drug discovery and drug development as well as the decreasing cost of genome sequencing which has lead to the huge growth of the market. It has been shown that epigentics has a great commercial application potential beyond cancer conditions and the market forecast for these areas increased significantly. Epigenetic mechanisms could participate directly or indirectly in the cancer, cardiovascular, reproductive, autoimmune disorders and different pathologies leading to cognitive functions deficiency.

These epigenetic pathways may be stimulated to certain extent due to external stimuli including the causative agents like heavy metals, pesticides, cigarette smoke, hormones, radiation etc. As a result, this may impact the function of these epigenetic pathways. The fact that epigenetics testing has already become a new approach in not only medical but also prenatal testing and also the rate of demand for such kits and assays is one of the major factors in future growth of the market. An upward health R&D spending trend all around the world is expected to provide this sector with a healthy growth over the projected period as well. For instance, according to the WHO report published in April 2023, the weighted average health GERD as% of GDP increased the most in high-income nations (0.25%) compared to the previous analysis (0.21%).

This can be attributed to the rise of GERD in several of these high-income nations, with the Republic of Korea reporting the biggest rise (from USD 3.8 billion to USD 4.5 billion in 2020), followed by Greece (from USD 513 million to USD 598 million in 2020). Over 15% was reported as an upsurge in both nations. In addition, for instance, in February 2021, the International Cancer Genome Consortium (ICGC) launched the ICGC ARGO Data Platform, a significant step forward after the ICGC 25K Data Portal. ARGO is a global initiative to promote cancer genetics by providing superior-quality clinical, genomic, and molecular data to worldwide researchers.

Market Dynamics:

Market Drivers-

Growing Investment in Research & Development

• Epigenetics have the chance to enrich the awareness of genes’ expression and its function which is related to a number of diseases among others, cancer, psychological issues, autoimmune diseases, and so forth. Major employers in the pharmaceutical and biotechnology industries have to spend lots of money to come up with drugs very quickly that will be able to medically modify the whole organism by epigenetic mechanisms. For example, in November 2023, Harbinger Health raised USD 140 million in Series B funding with $7 million coming from a Flagship Pioneering lead investor, and joined by new investors from across the globe including Pictet, Partners Investment, and Catalyst among others. The finances raised by the firm will be used to boost clinical trial being conducted by Cancer ORigin Epigenetics-Harbinger Health (CORE-HH). The firm' platform, HarbingerHx, is capable of spotting epigenetic marks connected to the growing of tumors because of its use of machine learning. The company plans to roll out its initial product – a lab-based immuno test meant for detection of early Cancer – in 2025.

Market Trends-

DNA Methylation is Expected to Hold a Major Share Over the Forecast Period.

• With largest share in the market forecast in study for the future period the DNA Methylation sector is envisaged to hold the key. DNA methylation was the main concern in the epigenetics market, and it is because, in cytosine ring a methyl group is only covalently attached, which eventually leads to inhibition of transcription. DNA samples are modified by bisulfite that causes deamination process. Afterward, PCR is conducted on these samples that leads to a part of the DNA sample called methylation-sensitive PCR (MSP). Various types of MSP do exist, real-time PCR for methylation detection, methyl light and quantitiative analysis of methylated alleles are just but a few types of MSP. At the time present, one can use other methods of quantitation, such as allele-specific bisulfite sequencing, southern-based method, lateral flow bisulfite pyrosequencing, and bisulfite PCR followed by MALDI - TOF MS, for methylation study. The progress of technology nowadays permits to have assay of the DNA methylation down to the locus level with the entire genome and it gives ground for market expansion.
• DNA methylation start-up organizations fundraising is an outstanding opportunity for market expansion. For instance, Think of Base Genomics, an epigenetics firm or DNA methylation analysis organization, that was founded in June 2020, with an outstanding crew and an overfunded USD 11 fundraising round of USD 9 million or GBP to develop its technology further. Oxford Sciences Innovation (OSIL) took up the lead, and the round included investors with knowledge in some of the most promising technological sectors, such as genomics and cancer. Through which the research on DNA methylation will be intensified and due to this, by the adoption of those reagents, kits, and instruments of DNA methylation will be upgraded, as a result of which the market growth will be promoted.
• In February 2021, Twist Bioscience Corporation launched the Twist NGS Methylation Detection System, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome. This will further lead to increased adoption of DNA methylation to study the human genome for research and develop novel therapies, thereby expected to drive this segment growth.
• Therefore, due to the abovementioned factors, the segment is expected to drive over the forecast period.

Market Restraining Factors-

Limited Applications of Epigenomic Data in Toxicology.

• Epigenetics data can supply instrumental information to reveal mechanism of toxical manner, although this may not be a valid measure in predicting the toxicity of a compound. This experimental branch of toxicology (toxicopigenetics) is still on its workbench, it is hazardously young and only several of its aspects have been touched by researchers much more work is necessary to figure out what is going on between epigenetic changes and toxicity. These profiling technologies are still relatively fresh and they may be taken to be tedious and costly. The FDA of the United States is still working on the rules on how epigenetic data can be used in toxicology testing which seems to be inhibiting companies from commercializing and developing functions of epigenetic-based toxicology tests.

Report Coverage:

The report will cover the qualitative and quantitative data on the global Epigenetics Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

By Product & Service (Kits & Reagents, Enzymes, Instruments and Accessories, Software, Service), By Methods (DNA Methylation, Histone Modifications, Other Methods), By Technique (NGS, PCR & qPCR, Mass Spectrometry, Sonication, Other Techniques), By Application (Oncology, Metabolic Diseases, Immunology, Developmental Biology, Cardiovascular Diseases, Other Applications), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics).

Report Scope and Segmentations:

Epigenetics Market Players Analysis:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Abcam plc (UK)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories Inc. (US)
• Promega Corporation (US)
• Revvity (US)
• Qiagen (Germany)
• New England Biolabs (US)
• Zymo Research Corporation (US)
• Diagenode SA (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• EpiGentek Group Inc. (US)
• EpiCypher (US)
• Fios Genomics (UK)
• GenomeScan (Netherlands)
• Creative Biogene (US)
• BPS Bioscienc Inc. (US)
• Abnova Corporation (Taiwan)
• Creative Diagnostics (US)
• Biomodal (UK)
• Integrated DNA Technologies Inc. (US)

Key Industry Developments:

In August 2023, PacBio (US) acquired Apton Biosystems (US)  to accelerate the development of a next-generation, high-throughput, short-read sequencer.

In March 2022, Thermofisher Scientific Inc (US) launched the CE IVD Marked Next Generation Sequencing Instrument designed to be used in in clinical laboratories to perform both diagnostic testing and clinical research on a single instrument.

In January 2022, Illumina, Inc. (US) entered into an agreement with SomaLogic (US) to introduce SomaScan Proteomics Assay in high throughput next-generation sequencing (NGS) platforms manufactured by Illumina.

Epigenetics Market Segmentation Analysis:

By Product & Service

• Enzymes
  • DNA-Modifying Enzymes
  • Protein-Modifying Enzymes
  • Other Enzymes
• Instruments & Accessories
• Reagents & Kits
  • 5-hmC & 5-mC Analysis Kit
  • Antibodies
  • Bisulfite Conversion Kits
  • ChiP-seq Kits
  • Histones
  • Whole Genome Amplification Kits
• Service
• Software

By Technique

• NGS
• PCR & qPCR
• Mass Spectrometry
• Sonication
• Other Techniques (Magnetic separators and Microarrays)

By Methods

• DNA Methylation
• Histone Modifications
• Other Methods (non-coding RNA and chromatin remodeling)

By Application

• Cardiovascular Diseases
• Developmental Biology
• Immunology
• Metabolic Diseases
• Oncology
• Other Applications (Neurology, Infectious Diseases, and Gynecology)

By End User

• Academic & Research Institutes
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, UK, Italy, Spain, Russia, Rest of Europe)
• Asia-Pacific (China, India, Japan, ASEAN, Rest of Asia-Pacific)
• LAMEA (Latin America, Middle East, Africa)

The report also helps in understanding Global Epigenetics Market dynamics, structure by analyzing the market segments, and project the Global Epigenetics Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Epigenetics Market make the report investor’s guide.

Global Epigenetics Market Segmentation Insights:

The market scope is segmented because of by Product & Service, by Methods, by Technique, by Application, by End User.

By Product & Service

Based on the Product & Service of the market is segmented into Kits & Reagents (Antibodies, ChiP-seq Kits, Bisulfite Conversion Kits, Whole Genome Amplification Kits, 5-hmC and 5-mC Analysis Kits, Histones, Other Kits & Reagents), Enzymes (DNA-modifying Enzymes, Protein-modifying Enzymes, Other Enzymes), Instruments and Accessories, Software, Service.

As the market is segmented on the basis of products, it covers reagents, kits, instruments and enzymes etc. and services. The reagents category represented 31.50% part of the overall revenue in 2022 and was the leading segment. A big pie of this category can be accredited to the high level of reagents consumption required in lab-based investigations. The scientific research of epigenetics works mainly with two types of reagents - histones and DNA modifiers. One of the main discoveries in genetics is 'epigenetics', this represents the idea of inherited, maybe reversible changes, in gene expression, that occurs but don't change the DNA sequence; however, this information transfers to the next generation. Changing the switch might cause the genes to be turned on or turned down, but without the DNA, the process all about how they work.

DNA methylation, RNA regulation, and histone modification are the ones that were the ingredients for comprehensive experiments. Components as such are necessary for gene controlling. From the other side, however, kits segment is theoretically prophesied to record the highest CAGR of approximately 15.4% over the same period. Therefore, the rescue kit demand is dependent on trends, such as an increase in the numbers of chronic illnesses, a growing aging population and an increase in the use of treatment approaches based on epigenetics. Alongside this, greater understanding, that combined with the increasing companies conducting development on those hi-tech kits, will contribute to the increasing popularity of these market sectors.

By Methods

Based on the Methods of the market is segmented into DNA Methylation, Histone Modifications, Other Methods (non-coding RNA and chromatin remodeling).

By methods, the line is categorized into major epigenetic mechanisms including DNA methylation, histone methylation, histone acetylation, major noncoding RNA, microRNA modification and chromatin structures. The pharmaceutical segment had the largest of 69.23% revenue in 2022 amongst all other segments. DNA marked chemically and enzymatically for epigenetic processes like DNA methylation wherein methylation of DNA is used as a method to determine the methylated DNA. The DNA methylation method will assist to unwind the complicated health processes associated with development of diseases that are disease-specific, and in the same way, design individualized drug therapies for patients depending on their individual need and as well as the treatment outcome. With demand for DNA methylation methods continuing to surge, the markets are anticipating growth. With the growing technology, we tend to see more and more genotypes-specific DNA methylation in a global scale being assessed on a regular basis.

The histone acetylation segment is going to retain the highest compound annual growth rate of 15.8% over the forecast period (2024-2032) thanks to the rise of the innovative techniques that help to enhance its efficiency. Extensive series of the investigations have shown that histone acetylation can recommend as target of therapy in diseases, like, solid tumors, inflammation, leukemia, etc. Among the HAT subfamilies that have been studied so far, those that stand out the most include NFA15, PCAF, GNC5, HTA1, HBO1, and MORC4. DNA methylation is a huge contributor to the cancer process which is mainly considered as an activity of HAT1. The broad scope in the therapeutic areas can create a blockbuster market, thus, the demand will increase in the period under study.

By Technique

Based on the Technique of the market is segmented into NGS, PCR & qPCR, Mass Spectrometry, Sonication, Other Techniques (magnetic separators and microarrays).

This means that the effective method for reading, analysing, and identifying epigenetic changes in DNA sequences is Next-Generation Sequencing (NGS). Another two techniques that are very significant in the epigenetics are luminescence (qPCR) and luminescence (qPCR), which help to get multiple copies of a specific section of DNA, including the parts that are being regulated by epigenetic mechanisms. A technology used in more epigenetics research is mass spectrometry, which measures the amount and presence of chemicals and proteins that form the building blocks of epigenetic processes. During its research, methods for breaking down cellular structures such as sonication are also used compare to DNA, RNA and proteins. Such approaches, together with additional methods like Chromatin immunoprecipitation (ChIP) and Bisulfite sequencing, form an important part of a general epigenome investigation and the consequent implications for health and diseases.

By Application

Based on the Application of the market is segmented into Oncology, Metabolic Diseases, Immunology, Developmental Biology, Cardiovascular Diseases, Other Applications (neurology, infectious diseases, and gynecology).

The world chapter, in turn, is based on applications and is further subdivided into an oncology segment, a metabolic diseases segment, an immunology segment, a developmental biology segment, a cardiovascular diseases segment, other applications. The oncology segment of this application generated the most sales, capturing a share of as much as 69.23% in 2023. Presently, cancer is the most investigated subject using these epigenetic methods. with cancer cases see a noticeable upswing, is most likely will there be an expansion on the market for pharmacogenetic diagnostics of cancer. With figures released by the American Cancer Society, it is projected that thirty-one hundred people will be diagnosed with cancer in 2022, with cancer epidemics resulting in about six hundred thousand deaths.

However, with the highest estimated CAGR of 15.7% among all the sub-end markets of the cancer market, the non-oncology application segment is forecast to be the fastest growing segment. The attention onto epigenetics studies were constantly increased by non-oncology disease indication. Consequent to investigated applications of epigenetics, doctors realize the opportunities to treat broad range of conditions, including neurological disorders, such as Alzheimer’s, Parkinson’s and others, as well as developmental disorders, such as ASD’s, CVD’s, metabolic disorders, and many others. The application of epigenetics not just in oncology but also in non-oncology indications would be high in the near future, which will positively reflect on the development of this section.

By End User

Based on the End User of the market is segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics.

On the basis of end user, the pharmaceutical & biotechnology companies segment held the largest epigenetics market size in 2023 and is expected to remain dominant during the forecast period, due to R & D for drug resistance developed by microorganisms, oncology, molecular aspects of cancer, and drug discovery for non-oncology applications.

Regional Snapshots:

North America was the largest regional market for epigenetics industry in 2023.

The epigenetics market has got divided into those five major parts with the names serving as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In the year 2023, North America takes the lead in the market share of epigenetics while the forecast shows the trend to maintain its position during the expected period. Presence of epigenetics production units and NGS-related initiations by government and private sectors for its development and adoption are some of the major characteristics of the market's growth.

Epigenetics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S.
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report:

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions:

• How much the global Epigenetics Market valued?
• Which region has the largest share in 2024 for the global Epigenetics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Epigenetics Market:

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Epigenetics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: